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Background: Breast ductal cancer in situ (DCIS) can recur or progress to invasive ductal cancer (IDC), and the
interim stage include DCIS with microinvasion (DCIS-Mi). In this article, we attempt to study the study the
differences of clinicopathological features, imaging data, and immunohistochemical-based subtypes among DCIS,
DCIS-Mi, and IDC.
Methods: In this retrospective study, we attempt to compare the clinicopathological features,
immunohistochemical results and imaging data of 866 patients (included 73 DCIS, 72 DCIS-Mi, and 721 IDC).
Results: Patients with DCIS and DCIS-Mi were younger than those with IDC (P = 0.007). DCIS and DCIS-Mi often
happened in premenopausal women while IDC was opposite (P <0.001). The incidence of IDC with node-positive
was significantly higher than it in DCIS and DCIS-Mi (P <0.001). We also observed that the Her2-positive was more
often found in patients with pure DCIS compared to those with DCIS-Mi and DCIS-I (P <0.001). There was a
significant difference between the four subgroups (Luminal-A, Luminal-B, ERBB2+, Basal-like) from DCIS, DCIS-Mi,
and IDC (P <0.001). Basal-like patients were fewer than other subgroups in DCIS, DCIS-Mi, and IDC. The incidence of
the first performance of ultrasound (catheter winded and nodular mass) and mammography (nodular mass) had
significantly difference among patients with DCIS, DCIS-Mi, and IDC (P <0.001).
Conclusions: Different clinicopathological, immunohistochemical, and imaging features among DCIS, DCIS-Mi, and
IDC indicate that they are distinct entities. A larger sample size is needed for further study.
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cancerBackground
Breast cancer is one of the most common malignant
tumors for women [1]. In recent years, the incidence of
breast cancer shows an increasing trend in China. Breast
ductal cancer in situ (DCIS) is a neoplastic proliferation
of epithelial cells confined to the ductal-lobular system
without tumor invasion through the basement mem-
brane [2]. Due to the extensively use of mammographic
imaging, the number of patients with DCIS and DCIS
with microinvasive (DCIS-Mi) is increasing. According* Correspondence: oncologyggl@163.com
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reproduction in any medium, provided the orto the criteria of the American Joint Committee on Can-
cer (AJCC), DCIS-Mi is defined as DCIS with a micro-
scopic focus of invasion ≤1 mm in the longest diameter,
which accounts for approximately 10% to 20% of DCIS
cases [3,4]. DCIS-Mi included the dominant lesion,
which is in-situ carcinoma and one or more foci of infil-
tration [5-8]. And international scholars consider that it
may be the interim stage in the progression from DCIS
to invasive breast cancer (IDC) [9,10]. Recent studies
revealed that DCIS-Mi was potential for invasion and
metastasis differentiated form pure DCIS, which also re-
sult for the different surgical strategy [11,12]. So DCIS-
Mi may represent a distinct entity.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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gression hypothesizes that IDC develops through se-
quential stages, from premalignant hyperplastic breast
lesions with or without atypia to carcinoma in situ to in-
vasive carcinoma [2,13-15]. Very few studies have paid
attention to the association of clinicopathological and
immunohistochemical (IHC) features among DCIS,
DCIS-Mi, and IDC. So we studied the differences of
clinicopathological features as well as IHC marker-based




We retrospectively collected 953 breast cancer patients
from February 2006 to April 2010. Among the 953
patients, 96 cases were excluded because their first
tumor lumpectomies were not in our hospital and there
were no data of specimens. Finally, 73 patients with
DCIS (9.29%), 72 patients with DCIS-Mi (9.16%), and
721 patients with IDC (83.26%) were enrolled in this re-
search. All the patients accepted physical examination,
chest radioscopy, mammography, ECG, complete blood
count, routine biochemical tests, and ultrasound (US)
(included breasts, axillary fossa, abdomen, and pelvis).
Each patient was treated with surgery by either lumpec-
tomy or mastectomy, and whether doing axillary lymph
node dissection was followed by adjuvant therapies
according to the standard guideline. All patients were
treated with lumpectomy or mastectomy (most with ax-
illary lymph node dissection) followed by adjuvant ther-
apies according to the standard guideline.
The age of the 866 patients ranged from 24 to 87 years
old (the median age at diagnosis was 52 years old). Me-
dian follow-up of those patients was 35 months (range,
1 to 118 months). We collected age, menopausal status,
tumor size, lymph node status, status of IHC (ER, PR,
and HER2), family history, and the history of breast sur-
gery. The pathologic and IHC outcomes were checked
by our senior pathologists in our hospital. This study
was approved by the Institutional Review Board of
Wenzhou Medicine University. Written informed con-
sents were obtained from the patients for publication of
this report.
Pathologic definition
DCIS is defined as clonal proliferation of cells growing
within the basement membrane-bound structures of the
breast [16]. DCIS-Mi is defined as DCIS with extension
of cancer cells beyond the basement membrane and in-
vasion ≤1 mm in the longest diameter. Those tumor
cells which are invasive breast ductal basement
membrane-bound structure were identified as IDC. The
specimens of all patients in our study were diagnosed bythree board-certified pathologists with a mean 11 years
(17, 9, and 7 years, respectively) of experience who were
not aware of the result of pathological examination from
the former pathologist.
Immunohistochemistry and scoring
The status of ER, PR, and HER2 confirmed by IHC
staining, which was performed through a standard oper-
ating procedure in our Department of Pathology. ER and
PR expression in the nuclei of tumor cells, Her-2 expres-
sion in the cytoplasm, positive cell is that cells contain
brown grains. A score of 0 required no staining seen, 1
required ≤25 % of cells positive, 2 required 25% to 50%
of cells stained, 3 required 50% to 75% of positive cells,
and 4 required >75% of staining cells.
Statistical analysis
We compared clinicopathological, IHC, and imaging
characteristics in the patient with DCIS, DCIS-Mi, and
IDC. For each group we estimated from the date of the
surgery by the life table. Tests of association and correl-
ation were conducted by using the n × n Pearson’s χ2
test (or Fisher’s exact test when appropriate). One-way
ANOVA was used to compare continuous variables
among two or more groups. P <0.05 was considered sta-
tistically significant. Statistical analyses were performed
using SPSS software version 17.0.
Results
The clinicopathological characteristics of patients are
shown in Table 1. Patients with DCIS and DCIS-Mi were
significantly younger than those with IDC (P = 0.007).
Patients with DCIS and DCIS-Mi were more often
found to have the status of premenopausal when com-
pare to those with IDC (P ≤0.001). The incidence of
lymph node metastasis from patients with IDC (38.75%)
was significantly higher compared to the patients with
pure DCIS (6.85%) and patients with DCIS-Mi (20.83%)
(P ≤0.001). We also observed that the number of status
of Her2 expressed positive in patients with DCIS and
DCIS-Mi was higher than in those with IDC (P <0.001)
but we found that the tumor size and family history of
breast cancer in a first-degree relative seemed to have
no difference in the three groups (P >0.05). We divided
patients into four subgroups: Luminal-A, Luminal-B,
ERBB2+, and Basal-like. We found no significant differ-
ence between the four subgroups regarding DCIS,
DCIS-Mi, and IDC.
Table 2 showed the clinical data of the first clinical
performances and diagnostic methods among DCIS,
DCIS-Mi, and IDC groups. For the first clinical perform-
ance for diagnosis, palpable mass was the main symptom
with no significant difference in the three groups (P = 0.52).
The incidence of nipple discharge was similar in the
Table 1 Characteristics of the three patient populations: DCIS, DCIS-Mi, and IDC
Parameter DCIS DCIS-Mi IDC P value
Total number 73 72 721
Age (mean ± SD) (year) 48.96 ± 1.13 49.34 ± 1.01 52.23 ± 0.43 0.007
Menopausal <0.001
Postmenopausal 21 (28.77) 28 (38.89) 415 (57.60)
Premenopausal 52 (71.23) 44 (61.11) 306 (42.40)
Family history 0.791
Positive 6 (8.2) 6 (8.3) 48 (6.7)
Negative 67 (91.8) 66 (91.7) 673 (93.3)
Tumor size (cm) 0.238
<2 38 (52.05) 32 (44.44) 302 (41.9)
≥2 35 (47.95) 40 (55.56) 419 (58.1)
Lymph node 0.000
Positive 5 (6.85) 15 (20.83) 279 (38.75)
Negative 68 (93.15) 57 (79.17) 442 (61.25)
ER 0.265
Positive 44 (60.27) 42 (58.33) 478 (66.25)
Negative 29 (39.73) 30 (41.67) 243 (33.75)
PR 0.736
Positive 41 (56.20) 37 (51.40) 405 (56.25)
Negative 32 (43.80) 35 (48.6) 316 (43.75)
Her-2 0.000
Positive 47 (64.38) 48 (66.67) 307 (42.60)
Negative 26 (35.62) 24 (33.33) 414 (57.40)
Over Her-2 0.000
Positive 35 (47.95) 36 (50.00) 180 (25.00)
Negative 38 (52.05) 36 (50.00) 541 (75.00)
Subtype 0.000
Luminal-A 23 (31.51) 21 (29.17) 325 (45.00)
Luminal-B 26 (35.62) 25 (34.72) 162 (22.50)
ERBB2+ 21 (28.77) 23 (31.94) 144 (20.00)
Basal-like 3 (4.10) 3 (4.17) 90 (12.50)
DCIS Ductal carcinoma in situ; Family history, Family history of breast cancer in a first-degree relative; IDC Infiltrating ductal carcinoma; Mi Microinvasion; SD
Standard deviation.
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but DCIS and DCIS-Mi was mainly yellow discharge,
IDC was mainly bloody. The second main clinical per-
formance was asymptomatic. Patients often see doctors
because of physical examination or abnormalities in
imaging (included US and mammography). There was
no difference between DCIS, DCIS-Mi, and IDC
groups in eczema and pain for the first clinical perfor-
mances (P < 0.05). For diagnostic methods, the pro-
portion of catheter winded was less in IDC than in
DCIS and DCIS-Mi (P ≤0.001), while the proportion
of the nodular mass was significantly more in IDC
than in DCIS and DCIS-Mi by US (P = 0.003). Therewas no difference between DCIS, DCIS-Mi, and IDC
in solid and cystic, structural disorder, and calcification,
respectively (P <0.05). For mammography feature, there
was significantly difference among them in the imaging
of nodular mass (P <0.05), but no difference in the
imaging of calcification (P =0.431).
A total of 215 of those 866 patients had a history of
breast operation and biopsy: 19 (26.0%) DCIS, 20
(27.8%) DCIS-Mi, and 176 (24.4%) IDC. We divided the
past disease into benign breast disease (BBD) and malig-
nant breast disease (MBD) which were showed in
Table 3. BBD is usually subdivided into non-proliferative
lesions (fibrosis, cysts, apocrine metaplasia, fibroadenoma),
Table 2 First clinical performances and diagnostic
methods of the three patient populations: DCIS, DCIS-Mi,
and IDC
Parameter DCIS DCIS-Mi IDC P value
Total number 73 72 721
First clinical performance
Nipple discharge 9 (12.3) 8 (11.1) 63 (8.7) 0.51
Bloody 4 (5.5) 3 (4.2) 44 (6.1) 0.776
Yellow 5 (6.8) 5 (6.9) 19 (3.3) 0.062
Palpable tumor 48 (65.8) 50 (69.4) 518 (71.8) 0.52
Pain 3 (4.1) 5 (5.9) 37 (5.1) 0.731
Eczema 1 (1.4) 1 (1.4) 29 (4.0) 0.22
Asymptomatic 12 (16.4) 8 (11.1) 74 (10.3) 0.27
Diagnostic methods
Ultrasound
Catheter widened 65 (89) 56 (77.8) 450 (62.4) 0.000
Solid and cystic 3 (4.1) 1 (1.4) 21 (2.9) 0.589
Nodular mass 56 (76.7) 53 (73.6) 648 (89.9) 0.003
Structural disorder 56 (76.7) 44 (61.6) 486 (67.4) 0.125
Calcifications 37 (50.7) 34 (47.2) 342 (47.7) 0.866
Mammography
Calcifications 60 (82.2) 63 (87.5) 631 (87.5) 0.431
Nodular mass 30 (41.1) 25 (34.7) 532 (73.8) 0.000
DCIS Ductal carcinoma in situ; IDC Infiltrating ductal carcinoma; Mi
Microinvasion.
Table 3 Past breast surgical or biopsy history of the three pa
Parameter DCIS
Total number 73




Apocrine metaplasia 1 (5.3)
Fibroadenoma 1 (5.3)
Lobular hyperplasia without atypia 8 (42.1)
Sclerosing adenosis 0 (0)
Papilloma 1 (5.3)
Atypical ductal hyperplasia 1 (5.3)
Atypical lobular hyperplasia 3 (15.8)
Malignant
IDC
Invasive lobular carcinoma 0
Invasive mucinous carcinoma 0
Invasive tubular carcinoma 0
DCIS 0
DCIS Ductal carcinoma in situ; IDC Infiltrating ductal carcinoma; Mi Microinvasion.
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without atypia, sclerosing adenosis, papilloma), and hyper-
plasia with atypia (atypical ductal hyperplasia, atypical
lobular hyperplasia). MBD includes IDC, invasive lobular
carcinoma, invasive mucinous carcinoma, invasive tubular
carcinoma, and DCIS. Then we found there was no differ-
ence between them in the past different breast benign dis-
ease types. And it was worth noting that lobular
hyperplasia without atypical accounts for most. At the
same time, one case of DCIS has gotten IDC in the past
breast surgical or biopsy history.
Discussion
Breast cancer is the second leading cause of death due
to cancer in women. In recent years, with the improve-
ment of diagnostic methods, the detection rate of breast
cancer has been increasing. DCIS accounts for approxi-
mately 10% to 15% of breast cancers detected by mam-
mography in China [17,18]. Now the data suggest that
carcinoma in situ can recur or progress to IDC and
breast DCIS-Mi is considered to be the interim stage in
the progression from DCIS to IDC [9,10]. The diagnosis
and the ability to predict the outcome of patients with
DCIS/DCIS-Mi are not satisfactory, leaded to inappro-
priate treatment choices. To the authors’ knowledge, the
hunt for molecular prognostic markers for DCIS and
DCIS-Mi has not succeeded. Therefore, we urgently
want to find the difference in clinicopathological, IHC,
and imaging features between DCIS, DCIS-Mi, and IDCtient populations: DCIS, DCIS-Mi, and IDC
DCIS-Mi IDC P value
72 721
20 (27.8) 176 (24.4) 0.795
4 (20) 29 (16.5) 0.700
2 (10) 23 (13.1) 0.864
1 (5.0) 5 (2.8) 0.789
1 (5.0) 6 (3.4) 0.885
6 (30.0) 64 (37.2) 0.728
0 (0) 1 (0.5)
2 (10.0) 9 (5.2) 0.724
2 (10.0) 10 (5.8) 0.780





Wei et al. World Journal of Surgical Oncology 2012, 10:262 Page 5 of 7
http://www.wjso.com/content/10/1/262in order to describe the process of DCIS to IDC from
the clinical aspects and discuss those results, contact
treatment, and reduce the incidence.
We studied the differences of clinicopathological, IHC,
and imaging features among DCIS, DCIS-Mi, and IDC.
We found that there was no significant difference be-
tween patients with DCIS, DCIS-Mi, and IDC in the first
symptoms in patients with previous breast history and
tumor size, but there were significant different in
patients’ age and menopausal state. It suggested that
even if patient get diseases the situations are consistent,
patients with old age and menopause were more likely
to have IDC. It was found that there was a significant
difference in the number of patients with lymph node
metastasis, and the former two were significantly less
than the latter, suggesting that the latter degree of malig-
nancy was significantly higher than former two. The first
clinical performance, family history, and previous history
of breast disease had no difference between DCIS,
DCIS-Mi, and IDC, while the degree of malignancy in
IDC was higher than in DCIS and DCIS-Mi. Except for
the age and the status of menopause, we found that US
and mammography played an important role in differen-
tiating DCIS, DCIS-Mi, and IDC. US was usually rou-
tinely performed for patients because of its advantages
(non-traumatic, repetitive), and it could find a mass
which is >2 cm [19]. This paper studied the difference of
US features among DCIS, DCIS-Mi, and IDC, and found
that the mass imaging of IDC patients by US were more
obvious, which may be due to IDC patients’ late inci-
dence, large mass, type of intraductal carcinoma, calcifi-
cation, and ill-defined infiltration. The number of DCIS
and DCIS-Mi patients with catheter widened imaging by
US was greater than IDC patients, which may be
explained that the latter’s large tumor image cover the
widened catheter. Mammography played an important
role in the early detection of breast cancer, especially in
DCIS. According to the literature, mammography was
important for detecting calcifications with high sensitiv-
ity, especially for the detection accuracy rate of DCIS.
We also studied the differences among them in the
mammography imaging, and found that there was no
significant difference in calcification, but significant dif-
ferences found in mass images. This may be due to
DCIS patients’ early incidence and large mass, and IDC,
DCIS, and DCIS-Mi all had calcification, so mammog-
raphy was not obvious, but important in the diagnosis of
early DCIS with micro-calcification.
In molecular biology, the breast is a sex hormone-
dependent organ. Its growth, development, and cell pro-
liferation are all influenced by estrogen and progester-
one. The regulation works by estrogen receptor (ER) and
progesterone receptor (PR) binding the receptors in the
breast cell. ER and PR play an important role in theincidence of breast cancer; normal breast tissue of ER-
positive expression will increase the risk of breast cancer
[20]. ER and PR were closely related to the prognosis
and endocrine therapy. The positive expression of endo-
crine therapy is an effective rate of 80% ER-positive tam-
oxifen treatment which can effectively reduce the local
recurrence of DCIS [21]. A report showed that ER and
PR expression range from 60% to 78%in DCIS [22]. This
article basically confirmed the literature. At the same
time, we found molecular markers ER and PR expression
were similar in DCIS, DCIS-Mi, and IDC, which sug-
gested hormone receptor status was determined in DCIS
stage. Although there was no accurate conclusion in the
breast cancer pathway, it may be a very close relation-
ship between DCIS and IDC in the event of the develop-
ment and occurrence.
Her-2 proto-oncogene product is one of the epidermal
growth factor receptor (EGFR) family, with binding with
ligand, changing the conformation, and causing a series
of ‘waterfall’ types of chain reaction, then accelerating
cell proliferation, accelerating cell cycle, and enhancing
malignant behavior. Most studies suggested that Her-2
over-expression was related to breast cancer invasion
and poor prognosis [23,24]. Our study found that Her-2
positive expression was 64.3% in DCIS, 66.67% in DCIS-
Mi, and 42.5% in IDC. Consistent with previous reports,
Her-2 express was lower in IDC than in DCIS, and was
over-expressed in DCIS [25-27]. At the same time, sev-
eral studies have found that normal breast tissue or be-
nign lesions generally do not over-express HER-2
[25,27]. Some researches thought Her-2 positive expres-
sion was due to the process of atypical hyperplasia in
DCIS, but in developing into IDC Her-2 frequently lose,
or Her-2 caused the direct immune response. Another
assumption was that the Her-2 negative in IDC was not
developed from DCIS, but from the atypical hyperplasia
[28,29]. According to data, we agreed with this hypoth-
esis. So we regarded Her-2 as one of the indicators of
prognosis and treatment.
We then tried to discover whether patients with DCIS,
DCIS-Mi, and IDC were associated with a history of
breast disease. Now due to the development of breast
imaging examination, lesions could be found in the early
stages. Breast disease history is helpful to evaluate the
subsequent risk of breast cancer. Previous reports
showed that women with proliferative breast lesions
without atypia have a slightly increased risk of breast
cancer, whereas women with atypical hyperplasia have a
substantially increased risk [13,30-34]. In this retrospect-
ive study of breast operation history or biopsy history of
patients who got DCIS, DCIS-Mi, and IDC, we found
there was no difference in the proportion of previous
breast operation and biopsy. We also found that DCIS,
DCIS-Mi, and IDC patients whose previous medical
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for the large proportion may be explained by its high in-
cidence in normal people. At the same time, hyperplasia
with atypia accounts less than lobular hyperplasia with-
out atypia, but it was accounted more than other breast
disease and it also agreed with the above point of view.
Finally, one case of DCIS patients recurred into IDC, in-
dicating that DCIS has the possibility of recurrence.
However, this retrospective study excluded patients with
breast cancer who had not performed biopsy or oper-
ation, so it was not very accurate, and further analysis
remains to be systematic prospective studies and large-
scale system examination.
Conclusions
In summary, through comparing DCIS, DCIS-Mi, and
IDC, we found that DCIS, DCIS-Mi, and IDC were dis-
tinct entities. A larger sample size is needed for further
study.
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